2011
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
Shapiro C, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein H, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. European Journal Of Cancer 2011, 47: 683-689. PMID: 21324674, PMCID: PMC4211594, DOI: 10.1016/j.ejca.2010.11.024.Peer-Reviewed Original ResearchConceptsChemotherapy-induced ovarian failureBone mineral densityRapid bone lossFollicle-stimulating hormoneZoledronic acidBone lossAdjuvant chemotherapyPremenopausal womenLumbar spineOvarian failureMineral densityMonths of amenorrhoeaGrade 3 toxicityMedian percent changeArm AAmino bisphosphonateMIU/Control groupPercent changeChemotherapyPercentage changeMonthsWomenRandomizationYears
2006
Pneumocystis Carinii Pneumonia During Dose-Dense Chemotherapy for Breast Cancer
Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis Carinii Pneumonia During Dose-Dense Chemotherapy for Breast Cancer. Journal Of Clinical Oncology 2006, 24: 5330-5331. PMID: 17114668, DOI: 10.1200/jco.2006.08.1083.Peer-Reviewed Original ResearchAnti-Infective AgentsAnti-Inflammatory AgentsAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCyclophosphamideDexamethasoneDoxorubicinFemaleFeverFilgrastimGranulocyte Colony-Stimulating FactorHumansMiddle AgedNeutropeniaPaclitaxelPneumonia, PneumocystisPolyethylene GlycolsPrednisoneRecombinant ProteinsTrimethoprim, Sulfamethoxazole Drug Combination